| HOME >> MEDICINE >> TECHNOLOGY |
SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today at the ASH Meeting in Atlanta, Georgia, that it will launch testing for the MPL W515 L/K mutation. This new test further expands the Genoptix service offering for patients with hematomalignancies, or cancers of the blood, to improve diagnosis and management. Genoptix believes it will be the first commercial hematology/oncology laboratory service provider to offer this test.
"Our ability to bring cutting-edge technologies to our physician partners, like both quantitative JAK2 and MPL testing, furthers our commitment to shepherding academic medicine to community-based practices," noted Tina Nova, Ph.D., President and CEO of Genoptix. Mike Nerenberg, M.D., Vice President of Business Development for Genoptix said, "MPL mutation analysis provides the hematologist/oncologist with a new diagnostic tool in the identification and management of myeloproliferative disorders, or MPD, a disease group that is becoming better understood with the availability of molecular assays such as this one."
MPL mutations, which affect the thrombopoietin receptor and result in the continuous activation of Janus 2 kinase (JAK2) and other pathways, are commonly associated with two myeloproliferative disorders, namely idiopathic myelofibrosis (IMF) and essential thrombocythemia (ET). MPL W515 L/K mutation analysis may be particularly useful for patients with suspected MPD that are negative for JAK2 mutations.
Genoptix utilizes Invader Plus(R) technology to achieve specific and sensitive detection of the MPL mutation.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.
Forward-Looking Statements.
Statements in t
'/>"/>
| SOURCE Genoptix, Inc. Copyright©2007 PR Newswire. All rights reserved |